Most Read Articles
Stephen Padilla, 03 Aug 2018
It appears that the two-dose AS04-adjuvanted HPV-16/18 vaccine (AS04-HPV-16/18v) is the most cost-effective choice for lowering the burden of cervical cancer through universal mass vaccination for 12-year-old girls in Singapore from the perspective of the healthcare payer (MOH Singapore), according to a recent study.
30 Oct 2019
Use of regional anaesthesia-analgesia using paravertebral blocks and the anaesthetic propofol does not lead to a lower risk of breast cancer recurrence after potentially curative surgery as compared with general anaesthesia with the volatile anaesthetic sevoflurane and opioid analgesia, according to a study.
31 Oct 2019
New drug application approved by US FDA as of 16 - 31 October 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
25 Apr 2020
The human papillomavirus (HPV) DNA vaccine (GX-188E) is effective against HPV type 16/18–associated cervical intraepithelial neoplasia (CIN) 3, according to the results of a phase II trial.

Disparity seen between anticoagulation prescription, guidelines

13 May 2019

Prescribing of prophylactic anticoagulation appears to be inconsistent with current practice guidelines, suggests a recent study. However, there appears to be lower thromboembolic events than recorded in previously published literature.

Of the 130 patients included in the study, 92 (70.8 percent) were prescribed lenalidomide and 38 (29.2 percent) pomalidomide. Nearly half of the patients (n=54; 41.5 percent) had a total risk score of 2. Aspirin 81 mg oral tablet was the most common prescription (n=53; 40.8 percent), followed by no anticoagulation (n=30; 23.1 percent).

A total of 27 patients (20.8 percent) were prescribed anticoagulation in accordance with National Comprehensive Cancer Network guidelines. The most common adverse event was incidence of deep venous thromboembolism (n=4; 3.1 percent), followed by major bleeding (n=1; 0.8 percent). There were no reported incidence of pulmonary embolism, myocardial infarction or stroke.

This retrospective study at an ambulatory oncology clinic evaluated overall adherence to guideline recommendations for anticoagulation therapy with lenalidomide and pomalidomide in multiple myeloma patients. The authors utilized chart reviews from the calendar years 2013–2016.

Prescription of appropriate anticoagulation upon initiation of therapy based on a list of predetermined risk factors was the primary endpoint, while secondary endpoints included incidence of deep venous thromboembolism, pulmonary embolism, myocardial infarction, stroke and major bleeding; initial anticoagulant prescribed; and whether or not anticoagulation was prescribed for another disease state.

“Lenalidomide and pomalidomide are two immunomodulatory medications with the potential to improve outcomes for patients with multiple myeloma; however, a black box warning for venous thromboembolism exists,” the authors said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Stephen Padilla, 03 Aug 2018
It appears that the two-dose AS04-adjuvanted HPV-16/18 vaccine (AS04-HPV-16/18v) is the most cost-effective choice for lowering the burden of cervical cancer through universal mass vaccination for 12-year-old girls in Singapore from the perspective of the healthcare payer (MOH Singapore), according to a recent study.
30 Oct 2019
Use of regional anaesthesia-analgesia using paravertebral blocks and the anaesthetic propofol does not lead to a lower risk of breast cancer recurrence after potentially curative surgery as compared with general anaesthesia with the volatile anaesthetic sevoflurane and opioid analgesia, according to a study.
31 Oct 2019
New drug application approved by US FDA as of 16 - 31 October 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
25 Apr 2020
The human papillomavirus (HPV) DNA vaccine (GX-188E) is effective against HPV type 16/18–associated cervical intraepithelial neoplasia (CIN) 3, according to the results of a phase II trial.